Gliclazide - Revisiting a Preferred Sulphonylurea in 2025 - Dr Silima Tarenia and Dr Shehzad Ruman Deeksha Bhandari13 Nov 2025 6:00 PM ISTOn this World Diabetes Day, we bring you a special episode of Dia Dialogues titled "Gliclazide - Revisiting a Preferred Sulphonylurea in 2025." ...
Aspirin in Obese T2D with Atherogenic Dyslipidemia: Identifying the Ideal Candidates Dr. Srinivas Kudva12 Nov 2025 12:00 PM ISTIndia faces a rapidly escalating triple syndemic of obesity, type 2 diabetes (T2D), and atherogenic dyslipidemia, conditions that frequently overlap...
Explainer video: Advise- Educating Patients about Addressing Glycemic and Weight Goals Deeksha Bhandari11 Nov 2025 11:45 AM ISTTalking about excess weight with people living with type 2 diabetes can be sensitive, but it is an important part of diabetes care. Evidence shows...
Risk Beyond Control: Inherited and Causal CV Risk Factors and the Role of Aspirin Dr. Prakash Kumar11 Nov 2025 11:30 AM ISTCardiovascular diseases (CVDs) are the leading cause of non-communicable disease (NCD) deaths in India, accounting for nearly 48% of all NCD...
Long-Acting Relief in Allergic Rhinitis: A Clinical Update on Dual Molecule Approach Dr. Kamal Kant Kohli10 Nov 2025 10:58 AM ISTAllergic rhinitis (AR) is a pervasive health burden affecting over 400 million individuals globally, presenting with a wide range of nasal symptoms...
H2 receptor antagonists (H2RAs) in Gastrointestinal Care of Neonates and Infants: Indian Paediatricians' Perspectives Dr. Garima Soni8 Nov 2025 11:50 AM ISTGastrointestinal (GI) conditions are common in neonates and infants. These may include Gastroesophageal Reflux (GER), Gastroesophageal Reflux...
Early Dose Adjustments Help Complete 2-Year Treatment Without Losing Efficacy in High-Risk Node-Positive EBC Dr. Garima Soni5 Nov 2025 12:51 PM ISTIn the video, Dr. Carlos Barrios, director and principal investigator of the oncology research center at Hospital São Lucas, and president of the...
A Hidden Epidemic: Addressing Visceral Fat and Insulin Resistance in Non-Obese T2DM with Pioglitazone-Based Therapies Dr. K M Suryanarayana VSM5 Nov 2025 11:15 AM ISTMetabolically unhealthy non-obese individuals (MUNO) comprise around 20% of the normal-weight population and have a 3.14-fold higher risk of...
Prediabetes and Cancer Risk: The Overlooked Connection Dr. Khushboo Agarwal3 Nov 2025 11:10 AM ISTPrediabetes burden is rising globally and in India. The latest IDF 2025 Atlas estimated that in 2024, 634.8 million adults (12%) worldwide had IGT,...
Dapagliflozin and Sitagliptin FDC: Exploring Early Initiation Benefits In Young Newly Diagnosed T2D in India Dr. Rajiv Kovil1 Nov 2025 10:34 AM ISTType 2 diabetes (T2D) is a growing epidemic in India. India has 101 million people with diabetes and 136 million with prediabetes, with disease onset...
Explainer video: Assess- Evaluating Patient Readiness for Diabetes- Management Strategies Deeksha Bhandari31 Oct 2025 12:01 PM ISTDiscussing weight with people living with type 2 diabetes can be difficult, but it is vital to improving care. Many patients with overweight or...
Indian Study Finds Vildagliptin SR Effective and Safe in Type 2 Diabetes Patients Uncontrolled on Metformin: PRIME-Vilda Trial Dr. Garima Soni30 Oct 2025 12:11 PM ISTVildagliptin SR 100 mg once daily has been shown to be effective and safe in improving glycemic control in Indian T2DM patients in India not...
